88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) has raised A$5 million in an oversubscribed share placing, giving the Alaska-focused explorer fresh funding to push ahead with pre-drilling work on its Augusta-1 well and related North Slope commitments.
The company placed 173.6 million new shares at A$0.029 each, or about £0.01508, with the price set at a 19.4% discount to the 24 March close and a 20.9% discount to the 10-day ASX VWAP before 23 March.
A pair of US jury verdicts this week has jolted social media giants — and potentially redrawn the legal lines around how their platforms are built.
In California, a jury on Wednesday found Meta Platforms Inc (NASDAQ:META, XETRA:FB2A, SIX:FB) and Alphabet Inc (NASDAQ:GOOG) liable for designing addictive platforms that harmed a young user, awarding roughly US$6 million in damages.
Are you starting to feel like we’re heading into a full-blown fuel crisis every time you fill up the tank? Turn on the news right now, and that’s exactly the picture being painted. Petrol prices are climbing, diesel is skyrocketing, and the narrative is quickly shifting toward fear. However, this is usually the point at which it pays to step back and examine what’s really happening. Yes, there is pressure in the system, but it isn’t the beginning of a long-term collapse.
Australia does have fuel reserves, and while they’re not massive, they are enough to manage short-term disruptions. The real pressure point right now is diesel, as it powers the backbone of the economy, from transport and mining to construction and agriculture. When diesel prices rise, that cost flows through to freight, food, and your weekly shop. So, rightly so, both businesses and households are feeling the pain. But here’s what’s missing from the headlines.
HyTerra Ltd (ASX:HYT, OTCQB:HYTLF) has signed a memorandum of understanding (MoU) with ARA Natural Resources LLC to jointly assess geologic hydrogen opportunities in Oman, giving the ASX-listed company an entry point into what it sees as one of the world’s most prospective natural hydrogen settings.
The 18-month exclusive collaboration brings together HyTerra’s geologic hydrogen exploration and appraisal expertise with ARA’s in-country operating, production and subsurface capabilities. The companies will review geological, geophysical and subsurface data across prospective areas in Oman, while also assessing regulatory, commercial and permitting pathways and engaging with government and industry stakeholders.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured $20 million in a strongly supported institutional placement, with the fresh capital to be used to scale manufacturing and commercial operations for its flagship point-of-care test — the FebriDx respiratory infection test — in the United States.
The raise was announced at the same time as the US FDA granted a Clinical Laboratory Improvement Amendments (CLIA) waiver for FebriDx®.
RLF AgTech Ltd (ASX:RLF) has secured $4.5 million in an institutional placement, with the company set to use the funds mainly for working capital as it pushes ahead with commercial execution.
Proceeds would be used predominantly to buy raw materials, secure inventory and fulfil customer pre-orders, positioning the business to respond to near-term demand.
Temas Resources Corp (CSE:TMAS, OTCQB:TMASF, FRA:26P, ASX:TIO) has established a Scientific Advisory Board (SAB) to support the commercial rollout and global development of its proprietary Regenerative Chloride Leaching (RCL) technology, as the company looks to expand licensing and partnership opportunities.
The board brings together hydrometallurgical and process experts to guide technical development, scale-up and deployment, while also assisting in assessing third-party mineral deposits and tailings for potential application of the RCL platform.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured a major regulatory milestone in the US, with the Food and Drug Administration granting a CLIA waiver for its flagship FebriDx point-of-care test, significantly expanding its commercial reach across primary and outpatient care settings.
The approval follows 510(k) clearance and enables FebriDx to be used in a far broader range of healthcare environments, triggering US$5.5 million in milestone payments and opening access to a substantially larger patient population and addressable market.